Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis

N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).

12 Mar 2014

STC Life and 97.7 B&H Clinic successfully treat pulmonary fibrosis patient

Stem cell research institute of STC Life Co., Ltd. (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Representative Doctor: WON JU JUNG) successfully finished mesenchymal stem cell therapy for the pulmonary fibrosis patient who visited Korea from Calgary, Canada.

12 Mar 2014

Genetic basis of hereditary disease causes severe brain atrophy in Jews of Moroccan ancestry

Ben-Gurion University of the Negev (BGU) researchers have unraveled the genetic basis of a hereditary disease that causes severe brain atrophy, mental retardation and epilepsy in Jews of Moroccan ancestry, according to a study published this week online in the Journal of Medical Genetics.

11 Mar 2014

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg.

10 Mar 2014

3D scaffolds bring hope for lung regeneration

In end-stage lung disease, transplantation is sometimes the only viable therapeutic option, but organ availability is limited and rejection presents an additional challenge.

10 Mar 2014

Research reveals 2 key mechanisms of oxidative stress regulation

Regulation of oxidative stress is critical to cell survival. New preclinical research from Roswell Park Cancer Institute (RPCI) has revealed two key mechanisms by which oxidative stress is regulated in normal and cancerous cells.

7 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Cystic fibrosis is a rare, life-shortening genetic disease for which there is no cure. It affects more than 75,000 people worldwide. In CF, thick, sticky mucus blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs airways in the lungs making it easier for bacteria to grow.

5 Mar 2014

Computational Fluid Dynamics helps patients with pulmonary disorders breathe easier

A more accurate and successful, yet complex approach used in designing an airplane is now taking off in the health care industry.

5 Mar 2014

Metabolic profiling of liver cells suggests new treatments for cirrhosis patients

In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University-led team of researchers examined the metabolic breakdown that takes place in liver cells during late-stage cirrhosis and found clues that suggest new treatments to delay liver failure.

5 Mar 2014

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

Extract from amur cork tree shows promise in treating pancreatic cancer

The bark of the Amur cork tree (Phellodendron amurense) has traveled a centuries-long road with the healing arts. Now it is being put through its paces by science in the fight against pancreatic cancer, with the potential to make inroads against several more.

3 Mar 2014

Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

Brisbane's water supply has been found to contain disease carrying bugs which can be directly linked to infections in some patients, according to a new study by QUT.

3 Mar 2014

Heat shock protein may be involved in folding processes of tau protein

Proteins like the so-called heat shock protein Hsp90 play an important role in almost all processes within human cells. They help other proteins fold into their three-dimensional structure or return damaged proteins back into their proper shape.

3 Mar 2014

Link found between pollutants and certain metabolic complications of obesity

A team of researchers at the IRCM in Montr-al led by R-mi Rabasa-Lhoret, in collaboration with J-r-me Ruzzin from the University of Bergen in Norway, found a link between a type of pollutants and certain metabolic complications of obesity. Their breakthrough, published online this week by the Journal of Clinical Endocrinology & Metabolism, could eventually help improve the prevention, diagnosis, and treatment of cardiometabolic risk associated with obesity, such as diabetes, hypertension and cardiovascular disease.

28 Feb 2014

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Ophthotech Corporation today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.

27 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Researcher identifies ''conductor'' in development of muscle tissue

A team led by Jean-Fran-ois C-t-, researcher at the IRCM, identified a ''conductor'' in the development of muscle tissue. The discovery, published online yesterday by the scientific journal Proceedings of the National Academy of Sciences (PNAS), could have an important impact on the treatment of muscular diseases such as myopathies and muscular dystrophies.

26 Feb 2014

Fibrosis News and Research

Further Reading

Aradigm reports record revenue of $4.6M in fourth quarter 2013

N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis

STC Life and 97.7 B&H Clinic successfully treat pulmonary fibrosis patient

Genetic basis of hereditary disease causes severe brain atrophy in Jews of Moroccan ancestry

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

3D scaffolds bring hope for lung regeneration

Research reveals 2 key mechanisms of oxidative stress regulation

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Computational Fluid Dynamics helps patients with pulmonary disorders breathe easier

Metabolic profiling of liver cells suggests new treatments for cirrhosis patients

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Extract from amur cork tree shows promise in treating pancreatic cancer

Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

Heat shock protein may be involved in folding processes of tau protein

Link found between pollutants and certain metabolic complications of obesity

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

FDA approves KALYDECO for people with cystic fibrosis

Researcher identifies ''conductor'' in development of muscle tissue

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News